We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

53 hedge funds and large institutions have $8.81M invested in Cardiff Oncology in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

2.37% less ownership

Funds ownership: 15.78% → 13.41% (-2.4%)

4% less funds holding

Funds holding: 55 → 53 (-2)

24% less capital invested

Capital invested by funds: $11.6M → $8.81M (-$2.83M)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

74% less call options, than puts

Call options by funds: $34K | Put options by funds: $129K

Holders
53
Holders Change
-2
Holders Change %
-3.64%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
12
Reduced
9
Closed
5
Calls
$34K
Puts
$129K
Net Calls
-$95K
Net Calls Change
+$119K

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$128K
2
Two Sigma Investments
Two Sigma Investments
New York
+$102K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$89.6K
4
Creative Planning
Creative Planning
Kansas
+$53.6K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$47.3K

Top Sellers

1
Citigroup
Citigroup
New York
-$1.07M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$407K
3
Morgan Stanley
Morgan Stanley
New York
-$303K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$158K
5
Millennium Management
Millennium Management
New York
-$89K
Name Holding Trade Value Shares
Change 		Change in
Stake
DWM
26
Denver Wealth Management
Colorado
$26.8K – – –
Charles Schwab
27
Charles Schwab
California
$24.1K – – –
FWS
28
FinDec Wealth Services
California
$23.5K – – –
Morgan Stanley
29
Morgan Stanley
New York
$23.1K -$303K -188,135 -92%
TIM
30
Tortoise Investment Management
New York
$22.1K – – –
HighTower Advisors
31
HighTower Advisors
Illinois
$22K – – –
Bank of New York Mellon
32
Bank of New York Mellon
New York
$21.1K – – –
GIA
33
Gladstone Institutional Advisory
Florida
$20.6K – – –
CC
34
Callan Capital
California
$20K – – –
Wells Fargo
35
Wells Fargo
California
$11.5K +$19 +12 +0.2%
AFIA
36
America First Investment Advisors
Nebraska
$5.88K – – –
UBS Group
37
UBS Group
Switzerland
$5.61K -$19.2K -11,876 -76%
Fidelity Investments
38
Fidelity Investments
Massachusetts
$3.73K -$7.75K -4,805 -65%
Osaic Holdings
39
Osaic Holdings
Arizona
$2.3K – – –
PNC Financial Services Group
40
PNC Financial Services Group
Pennsylvania
$2.23K – – –
GRP
41
Global Retirement Partners
California
$515 – – –
EBA
42
Eagle Bay Advisors
New York
$498 – – –
Fifth Third Bancorp
43
Fifth Third Bancorp
Ohio
$294 +$323 +200 New
NC
44
NewSquare Capital
Pennsylvania
$184 – – –
NFSG
45
Newbridge Financial Services Group
Florida
$169 – – –
US Bancorp
46
US Bancorp
Minnesota
$160 – – –
AF
47
Allworth Financial
California
$147 – – –
NA
48
NewEdge Advisors
Louisiana
$119 – – –
Northwestern Mutual Wealth Management
49
Northwestern Mutual Wealth Management
Wisconsin
$71 – – –
JP Morgan Chase
50
JP Morgan Chase
New York
$38 – – –
1
2
3

CRDF Hedge Fund Activity: Q2 2023 in Review

53 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2023, worth a combined $8.81M — down 24% from $11.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CRDF and 3 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 12 added.

The largest buyer was Citadel Advisors, adding an estimated $128K. The largest seller was Citigroup, exiting entirely with an estimated $1.07M sold.

  • 53 institutional investors held Cardiff Oncology (CRDF) as of Q2 2023, down from 55 in Q1 2023.
  • Funds reported $8.81M of Cardiff Oncology stock for Q2 2023, down 24% quarter-over-quarter.
  • 3 funds opened new Cardiff Oncology positions in Q2 2023 and 5 closed out, a net change of -2 holders.
  • The largest Cardiff Oncology buyer in Q2 2023 was Citadel Advisors, an estimated $128K added.
  • The largest Cardiff Oncology seller in Q2 2023 was Citigroup, an estimated $1.07M sold.

Based on aggregated 13F filings for Q2 2023.